Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADMS

Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis

Adamas Pharmaceuticals logo

About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)

Advanced Chart

Key Stats

Today's Range
$8.22
$8.22
50-Day Range
$7.97
$8.23
52-Week Range
$4.02
$9.15
Volume
N/A
Average Volume
692,487 shs
Market Capitalization
$376.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADMS Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Adamas One Corp (JEWL)
See More Headlines

ADMS Stock Analysis - Frequently Asked Questions

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to analysts' expectations of $25.07 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adamas Pharmaceuticals investors own include Rite Aid (RAD), VBI Vaccines (VBIV), Amarin (AMRN), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Exelixis (EXEL).

Company Calendar

Last Earnings
11/11/2021
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMS
CIK
1328143
Employees
138
Year Founded
2002

Profitability

EPS (Trailing Twelve Months)
($1.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.40 million
Net Margins
-71.11%
Pretax Margin
-71.11%
Return on Equity
N/A
Return on Assets
-42.96%

Debt

Debt-to-Equity Ratio
21.25
Current Ratio
4.53
Quick Ratio
4.17

Sales & Book Value

Annual Sales
$74.46 million
Price / Sales
5.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.47) per share
Price / Book
-17.49

Miscellaneous

Outstanding Shares
45,787,000
Free Float
37,133,000
Market Cap
$376.37 million
Optionable
Optionable
Beta
2.82

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ADMS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners